Australia markets closed

AC Immune SA (IMR.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
2.4100-0.0020 (-0.08%)
At close: 09:55PM CEST
Full screen
Previous close2.4120
Open2.6040
Bid2.3910 x 0
Ask2.5410 x 0
Day's range2.3720 - 2.6040
52-week range2.1000 - 8.2900
Volume0
Avg. volume590
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

    Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from The Michael J. Fox Foundation for AC Immune’s alpha-synuclein PET tracer program is now up to USD 3.7 million LAUSANNE, Switzerland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision

  • GlobeNewswire

    AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases

    Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalitiesIntegrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synucleinPrecisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharm

  • GlobeNewswire

    AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases

    Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CETDiscussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on vaccinations to treat a